PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (« GenSight Biologics » ou la « Société ») (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), une société biopharmaceutique spécialisée dans le développement et la commercialisation de…
Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
AUSTIN, Texas–(BUSINESS WIRE)–Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced positive topline results from its randomized, head-to-head Phase 1b JADE clin…
Uncategorized
Ray Therapeutics Appoints Scott Braunstein, M.D., as Chairman of the Board of Directors
BERKELEY, Calif.–(BUSINESS WIRE)–Ray Therapeutics Appoints Scott Braunstein, M.D., as Chairman of the Board of Directors
Uncategorized
Ashvattha Therapeutics Appoints Life Healthcare Veteran George Montgomery as Executive Chairman to Lead Corporate Development and Strategic Partnerships
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood-retinal barrier in areas of inflammation selectively targeting and reprogramming activa…
Uncategorized
Addressing Demodex essential for ocular surface management
Until recently, Demodex blepharitis was often overlooked as a common cause of irritation, according to a panel discussion at OSN New York.Eric D. Donnenfeld, MD, Jai G. Parekh, MD, MBA, and Darrell E. White, MD, discussed the impact that Demodex mites …
Uncategorized
SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease
BARCELONA–(BUSINESS WIRE)–SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced that the first patient has been dosed in the Part B dose-expansion por…